FEATURED INSIGHTS

• How mAbs Have Transformed Breast Cancer Treatment, And Where Is It Going Next

  Monoclonal antibody therapies are reshaping breast cancer treatment. Explore the latest manufacturing advances and research solutions helping developers accelerate therapy production at every stage.

• Patient-Derived Organoids For Cell Therapy Development

  Patient-derived organoids offer a more accurate way to test cell therapies by preserving the complex tumor environments that determine whether these treatments will actually work.

• Moving Beyond Animal Models With iPSC-Based Models

  Animal models are giving way to iPSC-based systems that better reflect human biology, offering researchers a more accurate and ethical path to drug discovery.

• Modeling Neurodegenerative Disorders: Where Are We Now?

  Neurodegenerative disease research faces a critical gap between symptom management and disease modification, making better preclinical models an urgent priority for the field.

• From 2D To Organ-On-A-Chip: Platforms Powering Modern Disease Models

  Disease modeling has evolved well beyond animal studies, and understanding which platform fits which research question is now a critical skill for modern biology teams.

• How Recombinant LAL Reagents Differ From Each Other

  Two types of recombinant endotoxin testing reagents are now available, each with distinct regulatory standing across pharmacopeias and implications for global method validation.

• Sterile Water Manufacturing And QC Testing

  Understanding which USP water monographs require bacterial endotoxin testing, sterility testing, or both helps laboratories select the right methods and avoid compliance gaps.

• Chemically Defined Medium For Intensified AAV And LV Production In HEK293 Cells

  Discover how a chemically defined medium designed for suspension HEK293 perfusion cultures supports intensified AAV and LV production processes, with viable cell densities exceeding 10^8 cells/mL.

• How Raw Materials, Media Composition, And Process Decisions Shape Advanced Cell Therapies

  Learn how variability in patient-derived starting materials, serum dependence, cytokine selection, and platform lock-in create downstream risks that proactive process design can help prevent.

• Predicting The Performance Of Perfusion Media In A Continuous Bioreactor

  Small-scale perfusion-mimic models can effectively predict media performance in continuous bioreactors to help optimize cell density, productivity, and scalability for CHO cell lines.

• High-Throughput Screening For High-Performance Cell Culture Media Development

  Learn about a high-throughput screening method that successfully optimized cell culture media, leading to a greater than 3-fold improvement in viral genome titer for AAV2 production.

• Advanced Approaches For Developing And Optimizing Perfusion Platforms

  Discover how to effectively use small-scale perfusion-mimic systems to identify optimal cell culture media and significantly increase volumetric productivity for large-scale biomanufacturing.

• Scalable Strategies For Intensified Viral Vector Production In HEK293 Cell Culture

  Learn a strategy for scalable bioprocessing and media optimization that drives intensified viral vector production. Achieve high cell density, excellent viability, and consistent AAV titers from 50mL to 5L.

• Chemically Defined HEK293 Viral Feed Boosts Viral Vector Production

  Discover how a chemically defined viral feed can boost AAV titers by up to 8-fold, supporting multiple serotypes and both suspension and adherent HEK293 cell lines, simplifying scalability.